TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16611442
Drug: Formulation B
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation B (Fansidar, Hoffmann La Roche, Basel, Switzerland, 500 mg sulfadoxine and 25 mg pyrimethamine)
Study: 6800389
Drug: Acebutolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acebutolol (200 mg orally)
Study: 19302250
Drug: Desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desloratadine 5 mg daily for 7 days
Study: 9291444
Drug: Implantable cardioverter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable cardioverter defibrillator (16 patients) or guided drug therapy (electrophysiologically guided class I antiarrhythmic drugs = 7 patients; Holter‐guided class III antiarrhythmic drugs = 16 patients)
Study: 9291444
Drug: Holter‐guided class
Approvals — FDA: no, EMA: no, PMDA: no
Description: Holter‐guided class III antiarrhythmic drugs
Study: 7949090
Drug: Intravenous aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous aspirin (500 mg)
Study: 7949090
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (0.3 mg)
Study: 3599793
Drug: One capsule
Normalized name: GABAdone Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule t.d.s. of terpene mixture (Rowachol)
Study: 3599793
Drug: Two capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two capsules t.d.s. of terpene mixture (Rowachol)
Study: 24579926
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg/d
Study: 25630641
Drug: Rifampicin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin (10 mg/kg body weight)
Study: 25630641
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus 150 mg of SQ109
Study: 25630641
Drug: Rifampicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin plus 300 mg of SQ109
Study: 21372751
Drug: DTaP‐IPV‐Hep B‐PRP‐T
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP‐IPV‐Hep B‐PRP‐T vaccine (Hexaxim)
Study: 21372751
Drug: Pentaxim and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaxim and Engerix B Pediatrico (Hep B monovalent) vaccines
Study: 15367726
Drug: Levetiracetam (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (1500 mg)
Study: 11347331
Drug: Methylprednisolone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (200 mg, i.v., every other day, 10 doses, total course dose 2 g)
Study: 11347331
Drug: Methylprednisolone and
Normalized name: methylprednisolone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone and cyclophosphamide (200 mg, i.v., on methylprednisolone-free days, 10 doses plus 200 mg i.v. once a month for 3 months, total course dose 2.6 g)
Study: 8636283
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin, 3.6‐mg implant) for 9 months
Study: 8636283
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin) + estrogen‐progestin replacement therapy (HRT)
Study: 8636283
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (goserelin)
Study: 1780418
Drug: Alprazolam (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (1.5 mg)
Study: 1334713
Drug: 2-Deoxyglucose (2DG,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-Deoxyglucose (2DG, 50 mg/kg)
Study: 6428577
Drug: Prednisolone 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone 0.75 mg/kg/day for four weeks
Study: 25148814
Drug: Daily remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily remote glucose monitoring (RGM)
Study: 17154092
Drug: Methylprednisolone iv
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone iv pulse therapy
Study: 17154092
Drug: Glucocorticoids (small
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (small doses and short periods)
Study: 17154092
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of pulse therapy (9-12g)
Study: 17154092
Drug: Cumulative dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative dose limited to 4.5-6g
Study: 11069196
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg risedronate daily for 2 weeks
Study: 8619935
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen treatment in ER positive subgroup
Study: 8619935
Drug: Adjuvant tamoxifen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant tamoxifen treatment in ER negative subgroup
Study: 26888587
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) treatment for 4 weeks
Study: 26888587
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (rehabilitation treatment as usual)
Study: 24628923
Drug: OnabotulinumtoxinA (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: OnabotulinumtoxinA (doses between 75 and 260 U, average 163 U per treatment cycle, administered every 12 weeks)
Study: 18034980
Drug: Olopatadine hydrochloride
Normalized name: Olopatadine Hydrochloride
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine hydrochloride nasal spray, 665 mcg (OLO)
Study: 18034980
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate monohydrate, 50 mcg (MM)
Study: 9927369
Drug: Inhaled lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled lidocaine
Study: 2075140
Drug: Alugastrin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alugastrin (30 mL liquid form)
Study: 2075140
Drug: Gastrin (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastrin (tablet form)
Study: 2075140
Drug: Wikalina (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wikalina (tablet form)
Study: 7459426
Drug: Buffered tablet
Normalized name: CVS Aspirin 325mg Buffered Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered tablet formulation of oxyphenbutazone
Study: 28614691
Drug: Intravenous amphotericin
Normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous amphotericin B deoxycholate (0.7 to 1.0 mg/kg/day)
Study: 28614691
Drug: Itraconazole capsules
Normalized name: Itraconazole Capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole capsules (600 mg/day for 3 days, then 400 mg/day for 11 days)
Study: 17305763
Drug: Esomeprazole 40
Normalized name: esomeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 40 mg once daily for 4 weeks
Study: 19601705
Drug: Antacid use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid use
Study: 6104743
Drug: Prenalterol (beta
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenalterol (beta 1‐adrenoceptor agonist)
Study: 29615092
Drug: Group-based metacognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based metacognitive therapy plus usual cardiac rehabilitation
Study: 25275411
Drug: Preservative-free fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free fixed dose combination of tafluprost 0.0015% and timolol 0.5%
Study: 25275411
Drug: Preservative-free non-fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preservative-free non-fixed combination of tafluprost 0.0015% and timolol 0.5%
Study: 21946361
Drug: Fluoxetine (FLX)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (FLX) 20 mg for 8 weeks
Study: 18713545
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy in addition to traditional therapy
Study: 9989194
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (21 mg/day)
Study: 9989194
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (14 mg/day)
Study: 2152664
Drug: Iron-supplemented milk
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron-supplemented milk (15 mg elementary iron as ferrous sulphate and 100 mg ascorbic acid per 100 g powder)
Study: 2152664
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (same milk with no supplement)
Study: 575490
Drug: 1020 mg
Normalized name: sodium bicarbonate 1020 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1020 mg creatinol O-phosphate (group A)
Study: 575490
Drug: 2040 mg
Normalized name: Mg
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2040 mg creatinol O-phosphate (group B)
Study: 575490
Drug: 3060 mg
Normalized name: HOMOSALATE 3060 mg in 45 mL / OCTOCRYLENE 4500 mg in 45 mL / OCTISALATE 2250 mg in 45 mL / AVOBENZONE 1350 mg in 45 mL TOPICAL CREAM [ZO Skin Health Daily Sheer Broad-Spectrum Sunscreen SPF 50 Water Resistant (40 Minutes)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3060 mg creatinol O-phosphate (group C)
Study: 30799646
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy (TT)
Study: 28183326
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza vaccine (IIV3) administered at day 1 and day 180
Study: 28183326
Drug: Tetanus‐diphtheria‐pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tetanus‐diphtheria‐pertussis vaccine administered at day 180
Study: 26615504
Drug: Crestal implants
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crestal implants (group A)
Study: 26615504
Drug: Subcrestal implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcrestal implants (group B)
Study: 7882873
Drug: Standard methadone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard methadone maintenance therapy (comparison group)
Study: 30132224
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of terlipressin (Group A)
Study: 30132224
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses of terlipressin (Group B)
Study: 30132224
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of terlipressin
Study: 28791734
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol dose at 0.4 or 0.6 g/kg
Study: 24056196
Drug: PD patients
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD patients OFF medication
Study: 24056196
Drug: PD patients
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD patients ON medication
Study: 11239189
Drug: Psychological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychological therapy (specific details not provided)
Study: 7965649
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (specific agents not detailed)
Study: 27529771
Drug: 1.9-g/d n-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.9-g/d n-3 PUFA treatment
Study: 23338733
Drug: Intra-articular lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular lidocaine injection
Study: 21126390
Drug: Spironolactone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (1 mg/kg per day) for 7 days
Study: 15905731
Drug: Single, dual,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, dual, and triple nucleoside reverse transcriptase inhibitors (NRTIs)
Study: 10589441
Drug: Other commercially
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other commercially available plant preparations
Study: 1931471
Drug: ALO1567 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO1567 (100 mg daily)
Study: 1931471
Drug: ALO1567 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALO1567 (200 mg daily)
Study: 31081693
Drug: GLP‐1RA (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP‐1RA (specific drugs include liraglutide, exenatide, and lixisenatide)
Study: 28278333
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg daily for 1 year)
Study: 28278333
Drug: Sorafenib (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (800 mg daily for 1 year)
Study: 24461877
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Study: 24461877
Drug: 3.6 g
Normalized name: ALCOHOL 3.6 g EXTRACORPOREAL CLOTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.6 g amino acids/(kg·d) plus 2-3 g lipid/(kg·d)
Study: 26028361
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g amino acids/(kg·d) (control group)
Study: 19593180
Drug: Venlafaxine (VEN)
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine (VEN) administered at daily dosages ranging from 75 to 150 mg.
Study: 15516884
Drug: Ketamine (0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.7 mg/kg)
Study: 15516884
Drug: Tramadol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol (15 mg/kg)
Study: 8155446
Drug: Desflurane with
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desflurane with low-dose (10 micrograms kg‐1) fentanyl
Study: 8155446
Drug: Fentanyl (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (high-dose 50 micrograms kg‐1) with midazolam
Study: 3412292
Drug: Intranasal pine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal pine extract (0.15 cc by metered dose spray, starting at 1/100,000 w/v, followed by 1/10,000, 1/1000 and 1/100 at 20 minute intervals)
Study: 31064896
Drug: Indigenous Ready‐to‐use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenous Ready‐to‐use Therapeutic Food (Medical Nutrition Therapy)
Study: 31064896
Drug: Standard Nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Nutrition Therapy
Study: 28433887
Drug: Clay Art
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clay Art Therapy (CAT)
Study: 26385052
Drug: L-arginine (6.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (6.4 g/day for 18 months)
Study: 21559279
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) administration within three hours of injury
Study: 19327910
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) to the head and neck
Study: 17573455
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine
Study: 9846910
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg at 8-h intervals for 5 days)
Study: 8635830
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ferrous sulphate (FeSO4) tablet per day for 15 weeks
Study: 8635830
Drug: FeSO4 tablets
Normalized name: Ferrous Sulfate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FeSO4 tablets along with 2,000,000 IU of vitamin A as single dose
Study: 2469747
Drug: organo-heparinoid cream
Normalized name: heparinoids
Approvals — FDA: no, EMA: no, PMDA: no
Description: organo-heparinoid cream (Hirudoid)
Study: 31195099
Drug: Zumba exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zumba exercise for 60 minutes twice weekly for 8 weeks
Study: 27628624
Drug: Oral Hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Hygiene Care Program (OHCP) administered twice a week for six sessions during in-hospital rehabilitation
Study: 31912791
Drug: Vemurafenib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vemurafenib (960 mg twice daily for 52 weeks)
Study: 22089718
Drug: Evacetrapib monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy, 30 mg/d
Study: 22089718
Drug: Evacetrapib monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy, 100 mg/d
Study: 22089718
Drug: Evacetrapib monotherapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evacetrapib monotherapy, 500 mg/d
Study: 22089718
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (simvastatin 40 mg/d, atorvastatin 20 mg/d, or rosuvastatin 10 mg/d) with evacetrapib, 100 mg/d
Study: 16381016
Drug: 9 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9 cycles of tailored and dose-escalated FEC (5-fluorouracil, epirubicin, cyclophosphamide)
Study: 16381016
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of standard FEC followed by high-dose chemotherapy
Study: 16381016
Drug: Monitoring BM
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monitoring BM changes at diagnosis and 6 months post-treatment
Study: 16647907
Drug: Raloxifene hydrochloride,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene hydrochloride, 60 mg once daily
Study: 16647907
Drug: Alendronate, 10
Normalized name: Alendronate, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate, 10 mg daily
Study: 10337502
Drug: Propionyl-L-carnitine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionyl-L-carnitine (1 g three times a day orally for 90 days)
Study: 7478455
Drug: Local application
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of tranexamic acid gel
Study: 6957978
Drug: Pirenzepine 25
Normalized name: pirenzepine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 25 mg b.i.d.
Study: 6957978
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg b.i.d.
Study: 6957978
Drug: Pirenzepine 50
Normalized name: pirenzepine 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirenzepine 50 mg t.d.s.
Study: 25690514
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion strategy (hemoglobin <11.3 g/dL; 7 mmol/L)
Study: 25690514
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion strategy (hemoglobin <9.7 g/dL; 6 mmol/L)
Study: 18434566
Drug: Etoricoxib 90
Normalized name: etoricoxib 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 90 mg every day
Study: 1283476
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + galanin (500 micrograms in 100 ml saline)
Study: 1283476
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + saline (100 ml)
Study: 2413379
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (vinblastine 6 mg/m2 i.v., bleomycin 15 mg i.m., methotrexate 40 mg/m2 i.v., cyclophosphamide 400 mg/m2 i.v., 5-fluorouracil 5 mg/kg i.v.)
Study: 22262728
Drug: Web-based diabetes-specific
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based diabetes-specific cognitive behavioral therapy (CBT) for depression, with minimal therapist support, delivered over 8 lessons.
Study: 17663804
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (4.4 ml/d)
Study: 15641055
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of disease-modifying antirheumatic drugs (DMARDs) with prednisolone
Study: 12932590
Drug: DDDR pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDDR pacing with long AV delay (DDDR-l)
Study: 12932590
Drug: DDDR pacing
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDDR pacing (both DDDR-s and DDDR-l)
Study: 10550443
Drug: Ibandronate (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate (2.5 mg)
Study: 6749526
Drug: Tolbutamide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 0.5 g administered 30 min prior to a standardized meal
Study: 6749526
Drug: Tolbutamide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 0.5 g administered immediately before a standardized meal
Study: 6749526
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered with a standardized meal
Study: 6749526
Drug: Tolbutamide 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolbutamide 0.5 g with the meal
Study: 29945500
Drug: Non-hydroxamate HDAC6
Normalized name: Carbamyl hydroxamate
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-hydroxamate HDAC6 inhibitors identified through pharmacophore modeling and molecular docking.
Study: 29945500
Drug: Pharmacophore model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacophore model (Hypo1) generated from 26 training set compounds.
Study: 17973208
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride (Group A; n=17)
Study: 17973208
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride and metformin (Group B; n=18)
Study: 17973208
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Premixed insulin (Group C; n=17)
Study: 16173134
Drug: Fumaria officinalis
Normalized name: Fumaria officinalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fumaria officinalis 1500 mg daily (fumitory group)